IMMUNE COMPLEX BINDING BY MODIFIED C-REACTIVE PROTEIN

修饰的 C 反应蛋白与免疫复合物的结合

• 批准号: 3488808
• 负责人: LAWRENCE A POTEMPA
• 金额: $ 5万
• 依托单位: IMMTECH INTERNATIONAL, INC.
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-07-01 至 1988-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3488808
• 关键词: acute phase protein; binding proteins; biomaterial development /preparation; biomaterial evaluation; biomaterial interface interaction; biomedical equipment development; blood coagulation; blood filtration; chemical binding; complement; disease /disorder model; drug interactions; extracorporeal circulation; human tissue; immune complex; immune complex diseases; immunochemistry; immunoglobulins; immunologic techniques; immunotherapy; laboratory rabbit; neoplasm /cancer immunotherapy; nonhuman therapy evaluation; plasmapheresis

Immune complexes (ICs) are formed by the binding of antibodies with antigens, the antigens being components of infectious organisms, other molecules foreign to the host organism, tumor- associated molecules, and in many diseases, normal tissue molecular components. ICs are removed from the circulation and tissues by a variety of normal mechanisms. However, their continued presence in autoimmune, malignant and infectious diseases, and deposition in tissues, contributes to compromised immune system function and inflammatory pathology. It is the long-term objective of this application to devise a technology for the extracorporeal removal of ICs from blood as an efficacious treatment modality for IC-involved diseases. We have discovered that a modified form of a normal human protein, elicited in response to inflammatory stimuli, has the ability to selectively bind ICs. This is a recent and heretofore unknown function of this molecule. The specificity and efficiency of the molecule's binding to ICs will be established by the research proposed in this application by using: model in vitro-formed ICs, ICs developed by antigen-induced IC disease in experimental animals, and with ICs in human sera derived from individuals with different IC-involved diseases. The technology will then be extended to the development of an extracorporeal device for clinical trails. The possible use of the IC-binding protein for the quantitation of ICs will also be explored.

免疫复合物（IC）是由抗体结合形成的 用抗原，抗原是传染性 生物体、宿主生物体的其他外来分子、肿瘤- 在许多疾病中，正常组织 分子组成 IC从流通中移除， 组织通过各种正常机制。 但他们的 持续存在于自身免疫性、恶性和感染性 疾病和组织中的沉积，有助于损害 免疫系统功能和炎症病理学。 是 本申请的长期目标是设计一种技术， 从血液中体外去除IC作为一种有效的 IC相关疾病的治疗方式。 我们已经发现 一种正常人类蛋白质的改良形式， 对炎症刺激的反应，有能力选择性地 绑定IC。 这是一个最近和迄今未知的功能， 分子。 分子结合的特异性和效率 将通过本研究中提出的研究建立IC 通过使用应用：模型在体外形成的集成电路，集成电路开发 实验动物中抗原诱导的IC疾病，以及IC 在来自具有不同IC参与的个体的人血清中， 疾病 该技术将扩展到 开发用于临床试验的体外装置。 的 IC结合蛋白定量IC的可能用途 也将被探索。